Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FABP6 | P51161 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8216463 | 1.00 | TSHR (0.47) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| SCHEMBL14136794 | 1.00 | TSHR (0.47) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| Hydrochloric Acid SCHEMBL928631 | 0.98 | TSHR (0.46) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| SCHEMBL67599 | 0.87 | TP53 (0.41) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| SCHEMBL2686070 | 0.87 | TP53 (0.41) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| SCHEMBL1812329 | 0.87 | TP53 (0.41) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| Hydrochloric Acid SCHEMBL28583358 | 0.85 | TP53 (0.40) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| Hydrochloric Acid SCHEMBL384129 | 0.85 | TP53 (0.40) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| Hydrochloric Acid SCHEMBL928017 | 0.85 | TP53 (0.40) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| SCHEMBL17804391 | 0.83 | TP53 (0.43) | TSHRALDH1A1MAPK1CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571881-A1 | PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | claimed |
| US-8329699-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | claimed |
| EP-2475667-A1 | INHIBITORS OF JAK | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| WO-2011029804-A1 | INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | claimed |
| EP-4739683-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008059-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| CN-117813293-A | Urea derivatives useful for the treatment of cancer | 蝎子疗法股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-111094265-B | Pyrazole derivative compound and use thereof | 韩美药品株式会社 | 2023-07-25 | — | — | CN | disclosed |
| WO-2022265993-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022149057-A1 | CDK INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2022-07-14 | — | — | WO | disclosed |
| CN-114340634-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-111094265-A | Pyrazole derivative compound and use thereof | 韩美药品株式会社 | 2020-05-01 | — | — | CN | disclosed |
| US-8329699-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2454262-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| CN-102471345-A | Pyrrolopyrazine inhibitors of kinases | ABBOTT LAB | 2012-05-23 | — | — | CN | disclosed |
| WO-2011029804-A1 | INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| US-7332509-B2 | Heterocyclic amides, a process for their preparation, compositions comprising them and their use | MERIAL LIMITED (US) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | CDC7, CDK7, CDK17 | TSHR 3427/4885ALDH1A1 3421/4885MAPK1 201/4885 |
| US-20110059118-A1 | INHIBITORS OF JAK | JAK1, JAK3, JAK2 | TSHR 974/4885ALDH1A1 4659/4885MAPK1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.